Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes.

Journal of Internal Medicine
F Jansson SigfridsPer-Henrik Groop

Abstract

We aimed to assess whether remnant cholesterol concentration and variability predict the progression of diabetic nephropathy (DN) and severe diabetic retinopathy (SDR) in type 1 diabetes. This observational prospective study covered 5150 FinnDiane Study participants. Remnant cholesterol was calculated as total cholesterol - LDL cholesterol - HDL cholesterol and variability as the coefficient of variation. DN category was based on consensus albuminuria reference limits and the progression status was confirmed from medical files. SDR was defined as retinal laser treatment. For 1338 individuals, the severity of diabetic retinopathy (DR) was graded using the ETDRS classification protocol. Median (IQR) follow-up time was 8.0 (4.9-13.7) years for DN and 14.3 (10.4-16.3) for SDR. Remnant cholesterol (mmol L-1 ) was higher with increasing baseline DN category (P < 0.001). A difference was also seen comparing non-progressors (0.41 [0.32-0.55]) with progressors (0.55 [0.40-0.85]), P < 0.001. In a Cox regression analysis, remnant cholesterol predicted DN progression, independently of diabetes duration, sex, HbA1c , systolic blood pressure, smoking, BMI, estimated glucose disposal rate and estimated glomerular filtration rate (HR: 1.51 [1....Continue Reading

References

Aug 5, 1982·The New England Journal of Medicine·P J NestelM H Tan
Aug 13, 2003·Kidney International·Alicia J JenkinsUNKNOWN DCCT/EDIC Research Group
Jan 28, 2005·The New England Journal of Medicine·Solomon TesfayeUNKNOWN EURODIAB Prospective Complications Study Group
Feb 2, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Katsuyuki NakajimaAkira Tanaka
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Oct 10, 2009·Diabetologia·N TolonenUNKNOWN FinnDiane Study Group
Feb 27, 2010·Diabetes Care·Kustaa HietalaUNKNOWN FinnDiane Study Group
Feb 22, 2011·Annals of Neurology·Anette VarboMarianne Benn
May 4, 2011·Nature Reviews. Nephrology·Juan F Navarro-GonzálezJavier García-Pérez
Jul 14, 2012·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Y-H ChangY-J Lee
Dec 26, 2012·Journal of the American College of Cardiology·Anette VarboBørge G Nordestgaard
Dec 18, 2013·Journal of Atherosclerosis and Thrombosis·Mika SonodaMasaaki Inaba
Jun 25, 2014·Nutrition & Metabolism·Mariann I LasseniusMarkku Lehto
Aug 27, 2015·Diabetes·Jennifer N ToddJose C Florez
Feb 20, 2016·Journal of Clinical Lipidology·Gianluca BardiniEdoardo Mannucci
May 27, 2017·Current Opinion in Lipidology·Anette Varbo, Børge G Nordestgaard
Jul 3, 2018·Diabetes, Obesity & Metabolism·Valma HarjutsaloUNKNOWN FinnDiane Study Group
Mar 6, 2019·Diabetes Care·Bruce A PerkinsUNKNOWN Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Gro
Oct 24, 2019·JAMA Cardiology·Allan D SnidermanBrian A Ference

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

© 2021 Meta ULC. All rights reserved